ReviewCancer journal (Sudbury, Mass.)
Antiangiogenic therapy for glioblastoma.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Molecular insights into glial neuroimmune cross reactivity with CNS antigens and its role in neuroinflammation.Inflammopharmacology · 2026Pooled it
- A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).Neuro-oncology · 2020Trial
- Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Polyethylene Glycol Mediated Xeno-Free Isolation of Human Umbilical Cord Tissue-derived Mesenchymal Stem cells secreted Small Extracellular Vesicles: An Optimization, Characterization, and its Functional Evaluation Study in Glioblastoma.Applied biochemistry and biotechnology · 2026Article
- Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.Theranostics · 2026Review
- Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.Journal of neuro-oncology · 2025Article
- Decoding the Nexus: Cellular and Molecular Mechanisms Linking Stroke and Neurotoxic Microenvironments in Brain Cancer Patients.Biomolecules · 2024Review
- Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma.Cancer medicine · 2023Article
- Article
- The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.Cancers · 2021Review
- Lipid-Based Nanocarriers for The Treatment of Glioblastoma.Advanced nanobiomed research · 2021Article
- Intracellular Progesterone Receptor and cSrc Protein Working Together to Regulate the Activity of Proteins Involved in Migration and Invasion of Human Glioblastoma Cells.Frontiers in endocrinology · 2021Article
- Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes.Frontiers in radiology · 2021Review
- Distinction of Microglia and Macrophages in Glioblastoma: Close Relatives, Different Tasks?International journal of molecular sciences · 2020Review
- 3D bioprinting of glioblastoma models.Journal of 3D printing in medicine · 2020Review
- A three-dimensional (3D) organotypic microfluidic model for glioma stem cells - Vascular interactions.Biomaterials · 2019Article
- The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: in 3D in Vitro ModelAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.Biomaterials · 2018Article
- PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastomas are among the most vascular tumors due to the expression of a variety of proangiogenic factors. New drug regimens are being developed to target angiogenesis in an attempt to arrest tumor growth. In particular, the vascular endothelial growth factor (VEGF) pathway has been a prime drug target. Preliminary results with anti-VEGF agents have been promising with prolonged progression-free survival reported. In addition, the antipermeability effects of anti-VEGF agents have important consequences for tumor imaging and for patient quality of life by decreasing corticosteroid dependence. Unfortunately, the response to anti-VEGF therapy is transient, and the majority of patients eventually relapsed, so more work is needed to understand the mechanisms of tumor escape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.